Recent News

• 06.06.2025 - Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
• 06.06.2025 - Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
• 06.05.2025 - Jefferies Global Healthcare Conference
• 06.05.2025 - Jefferies Global Healthcare Conference
• 06.03.2025 - Candel Therapeutics’ Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
• 06.03.2025 - Candel Therapeutics’ Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
• 05.28.2025 - Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
• 05.28.2025 - Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
• 05.27.2025 - Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
• 05.27.2025 - Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

Recent Filings

• 06.06.2025 - 8-K Current report
• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.06.2025 - EX-99.1 EX-99.1
• 06.06.2025 - 3 Initial statement of beneficial ownership of securities
• 05.28.2025 - 8-K Current report
• 05.28.2025 - EX-99.1 EX-99.1
• 05.22.2025 - 8-K Current report
• 05.22.2025 - EX-99.1 EX-99.1